Patient & Visitor InformationContact Us
  • Breast Protocols

  • Adjuvant

    1. CTSU B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
      PI: William Sikov, MD
      Sites: Rhode Island Hospital, The Miriam Hospital

    2. CTSU S1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
      PI: William Sikov, MD
      Sites: Rhode Island Hospital, The Miriam Hospital

    3. RTOG 0413/NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer
      PI: Thomas DiPetrillo, MD
      Sites: Rhode Island Hospital, The Miriam Hospital

    4. BrUOG 251: Accerlerated Partial Breast Irradiation Using Non-Invasive Image-Guided Breast Brachytherapy (AccuBoost) For Early Stage Breast Cancers: A Toxicity Assessment
      PI: Jaroslaw Hepel, MD
      Sites: Rhode Island Hospital

    5. ACCRU APHINITY: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer (BIG 4‐11/BO25126/TOC4939G)
      PI: William Sikov, MD
      Sites: Rhode Island Hospital, The Miriam Hospital